Efficacy of Nigella sativa L. seed oil in treatment of type 2 diabetes
Phase 3
- Conditions
- Diabetes.E10, E14,Non-insulin-dependent diabetes mellitus
- Registration Number
- IRCT201207301157N7
- Lead Sponsor
- Vice chancellor for research, Institute of Medicinal Plants
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Type 2 diabetic patients with fasting blood glucose levels between 140 and 180 mg/dl; body weight between 55 and 75 kg; age between 34 and 63 years; disease duration of 2 to 8 years; taking no more than two 500 mg metformin and two 5 mg glyburide tablets every day.
Exclusion criteria: Patients receiving insulin therapy; patients with cardiac, renal, hepatic and hematological diseases; patients with a history of gallstones or gall bladder surgery; patients using estrogen, steroid, beta-blocker and thiazide drugs; pregnant and breast-feeding women; alcohol consuming and cigarette smoking patients.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting blood glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level was determined in laboratory by commercially available kit.;Glycosylated hemoglobin (HbA1C). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood HbA1c level was determined in laboratory by commercially available kit.;2 hours postprandial blood glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level was determined in laboratory by commercially available kit.
- Secondary Outcome Measures
Name Time Method